Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and
represents a high-grade neoplasm of skeletal myoblast-like cells. Decades of clinical and …

The prognosis for children and adolescents with rhabdomyosarcoma (RMS) has improved
with refinements in multi‐modal therapy. Since 1972, the Intergroup Rhabdomyosarcoma …

Background For more than three decades, standard treatment for rhabdomyosarcoma in
Europe has included 6 months of chemotherapy. The European paediatric Soft tissue …

Purpose The objective of this phase II trial was to assess the efficacy and toxicity of weekly
paclitaxel for patients with metastatic or unresectable angiosarcoma. Patients and Methods …

Background Rhabdomyosarcoma is an aggressive tumour that can develop in almost any
part of the body. Doxorubicin is an effective drug against rhabdomyosarcoma, but its role in …

Abstract In the US, approximately 850–900 children are diagnosed each year with soft tissue
sarcomas (STS). Key findings from recent Children's Oncology Group (COG) clinical trials …

PURPOSE The primary aim of this clinical trial was to prioritize bevacizumab or temsirolimus
for additional investigation in rhabdomyosarcoma (RMS) when administered in combination …

Survival outcomes for adolescent and young adult patients with soft tissue sarcomas lag
behind those of children diagnosed with histologically similar tumours. To help understand …

Relapsed rhabdomyosarcoma (RMS) represents a significant therapeutic challenge. Nearly
one-third of patients diagnosed with localized RMS and over two-thirds of patients with …

Advanced soft‐tissue sarcomas are usually resistant to cytotoxic agents such as doxorubicin
and ifosfamide. Antitumor activity has been observed for gemcitabine and docetaxel …